Idera Pharmaceuticals, Inc.

Yukui Li

Sudhir Agrawal

Ekambar R Kandimalla

Dong Yu

Daqing Wang

Lakshmi Bhagat

FuGang Zhu

Mallikarjuna Putta

Tao Lan

Fu-Gang Zhu

Mallikarjuna Reddy Putta

Agrawal Sudhir

Bhagat Lakshmi

Zhu Fugang

Wang Daqing

The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8

The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.

Growing community of inventors

Newton, MA, United States of America

Yukui Li